BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: 5-Fluorouracil (5FU)
Drug: Paclitaxel
Drug: Carboplatin
Drug: Leucovorin
Drug: Irinotecan
Drug: BMS-906024

First Posted Date: 2012-07-31

Last Posted Date: 2020-01-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 141

Registration Number: NCT01653470

Locations: 🇺🇸
Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇨🇦
Local Institution, Ottawa, Quebec, Canada

A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia

Phase 1

Terminated

Conditions: Hypercholesterolemia

Interventions: Drug: BMS-852927
Drug: Placebo

First Posted Date: 2012-07-27

Last Posted Date: 2013-08-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 97

Registration Number: NCT01651273

Locations: 🇩🇪
Local Institution, Neuss, Germany

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)

Phase 3

Completed

Conditions: Squamous Cell Non-small Cell Lung Cancer

Interventions: Biological: Nivolumab
Drug: Docetaxel

First Posted Date: 2012-07-17

Last Posted Date: 2022-12-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 272

Registration Number: NCT01642004

Locations: 🇺🇸
Local Institution - 0003, Baltimore, Maryland, United States
🇺🇸
Local Institution - 0017, Seattle, Washington, United States
🇺🇸
Local Institution - 0001, Seattle, Washington, United States

and more 121 locations

Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Relapsed and/or Refractory Multiple Myeloma

Interventions: Biological: Elotuzumab
Biological: Thalidomide
Biological: Dexamethasone
Biological: Cyclophosphamide

First Posted Date: 2012-07-02

Last Posted Date: 2017-04-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 51

Registration Number: NCT01632150

Locations: 🇪🇸
Local Institution, Zaragoza, Spain

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Phase 2

Withdrawn

Conditions: Hepatitis C Virus

Interventions: Drug: Daclatasvir
Drug: BMS-986094
Drug: Ribavirin
Drug: Placebo for BMS-986094

First Posted Date: 2012-06-28

Last Posted Date: 2014-05-09

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT01629732

Locations: 🇺🇸
Local Institution, Orlando, Florida, United States

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

Phase 1

Completed

Conditions: Neoplasms by Site

Interventions: Biological: Denenicokin
Biological: Nivolumab

First Posted Date: 2012-06-28

Last Posted Date: 2015-03-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 33

Registration Number: NCT01629758

Locations: 🇺🇸
Oncology Research Associates, Pllc D/B/A, Scottsdale, Arizona, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States

and more 2 locations

Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus

Phase 2

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: Daclatasvir
Drug: Simeprevir
Drug: Ribavirin

First Posted Date: 2012-06-27

Last Posted Date: 2017-02-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 230

Registration Number: NCT01628692

Locations: 🇪🇸
Local Institution, Valencia, Spain
🇺🇸
Johns Hopkins University, Lutherville, Maryland, United States
🇺🇸
San Francisco General Hospital, San Francisco, California, United States

and more 5 locations

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

Phase 1

Completed

Conditions: Advanced Melanoma
Metastatic Melanoma

Interventions: Biological: Nivolumab
Drug: Ipilimumab

First Posted Date: 2012-06-18

Last Posted Date: 2024-04-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 170

Registration Number: NCT01621490

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇳🇱
Local Institution - 0016, Amsterdam, Netherlands
🇺🇸
University Of Chicago, Chicago, Illinois, United States

and more 11 locations

Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

Phase 3

Terminated

Conditions: HIV

Interventions: Drug: Atazanavir
Drug: Ritonavir
Drug: Tenofovir/Emtricitabine
Drug: Lamivudine

First Posted Date: 2012-06-15

Last Posted Date: 2024-01-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 3

Registration Number: NCT01620944

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Biological: Pegylated interferon lambda (pegIFNλ)
Biological: Pegylated interferon alfa-2a (pegIFNα-2a)
Drug: Ribavirin
Drug: Placebo matching Daclatasvir
Drug: Daclatasvir

First Posted Date: 2012-06-11

Last Posted Date: 2015-10-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 880

Registration Number: NCT01616524

Locations: 🇺🇸
Precision Research Institute, Llc, San Diego, California, United States
🇺🇸
Medical Associates Research Group, San Diego, California, United States
🇺🇸
Orlando Infectious Disease Center, Orlando, Florida, United States

and more 16 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy